Daniel Foxler
Head of Cell Biology & Assay Development LabGenius
Dr. Dan Foxler is Head of Cell Biology & Assay Development at LabGenius. He has over 15 years of experience in immunotherapy‑focused biotechnology, including prior roles at Adaptate Biotherapeutics and GammaDelta Therapeutics. His expertise spans functional characterization of therapeutic candidates, molecular biology, and preclinical assay design. Dr. Foxler holds a PhD in Oncology and Cancer Biology from the University of Nottingham.
Seminars
Wednesday 24th June 2026
Harnessing Avidity-Based Binding Logic to Improve T-cell Engager Selectivity for Solid Tumors
12:00 pm
- Integrating high-throughput functional cell-based assays with machine learning to enable rapid optimization of preclinical candidates
- Solving on-target/off-tumor toxicities through avidity-driven tumor selectivity
- Progressing our lead asset LGTX-101 (Nectin-4 x CD3 T-cell engager) through IND enabling studies demonstrating robust in vitro, in vivo and biophysical characteristics
